Aeon Biopharma IncNYSE American:AEON
- LAST PRICE5.0700
- TODAY'S CHANGE (%)0.8200 (19.2941%)
- Bid / Lots5.1000/ 9
- Ask / Lots6.0000/ 36
- Open / Previous Close4.1300 / 4.2500
- Day Range
- 52 Week Range
- Volume133,325
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AEON |
|---|---|---|
| 09:32 ET | 252 | 4.13 |
| 09:56 ET | 100 | 4.3745 |
| 10:19 ET | 725 | 4.19 |
| 10:21 ET | 740 | 4.19 |
| 10:26 ET | 500 | 4.15 |
| 10:28 ET | 100 | 4.2 |
| 10:32 ET | 708 | 4.15 |
| 10:33 ET | 100 | 4.2 |
| 10:37 ET | 200 | 4.28 |
| 10:39 ET | 1090 | 4.385 |
| 10:44 ET | 859 | 4.35 |
| 10:48 ET | 100 | 4.36 |
| 10:51 ET | 100 | 4.395 |
| 10:57 ET | 100 | 4.425 |
| 11:00 ET | 415 | 4.4 |
| 11:02 ET | 600 | 4.46 |
| 11:04 ET | 100 | 4.44 |
| 11:08 ET | 100 | 4.5052 |
| 11:11 ET | 200 | 4.57 |
| 11:13 ET | 100 | 4.62 |
| 11:15 ET | 500 | 4.62 |
| 11:18 ET | 100 | 4.76 |
| 11:20 ET | 2249 | 4.77 |
| 11:22 ET | 100 | 4.84 |
| 11:27 ET | 200 | 4.9 |
| 11:29 ET | 2000 | 4.9 |
| 11:31 ET | 707 | 4.88 |
| 11:40 ET | 400 | 4.75 |
| 11:42 ET | 300 | 4.63 |
| 11:44 ET | 245 | 4.77 |
| 11:49 ET | 200 | 4.6739 |
| 11:56 ET | 1089 | 4.68 |
| 11:58 ET | 1588 | 4.72 |
| 12:00 ET | 200 | 4.79 |
| 12:07 ET | 100 | 4.7037 |
| 12:09 ET | 400 | 4.7 |
| 12:14 ET | 930 | 4.7 |
| 12:21 ET | 200 | 4.65 |
| 12:25 ET | 200 | 4.61 |
| 12:27 ET | 301 | 4.6736 |
| 12:34 ET | 100 | 4.52 |
| 12:50 ET | 200 | 4.52 |
| 12:59 ET | 200 | 4.73 |
| 01:08 ET | 600 | 4.66 |
| 01:10 ET | 100 | 4.675 |
| 01:30 ET | 200 | 4.71 |
| 01:32 ET | 2031 | 4.75 |
| 01:33 ET | 1639 | 4.75 |
| 01:35 ET | 100 | 4.76 |
| 01:37 ET | 2145 | 4.79 |
| 01:39 ET | 400 | 4.79 |
| 01:42 ET | 3393 | 4.7 |
| 01:44 ET | 900 | 4.5777 |
| 01:46 ET | 7856 | 4.63 |
| 01:48 ET | 3000 | 4.61 |
| 01:50 ET | 7855 | 4.55 |
| 01:51 ET | 1090 | 4.7 |
| 01:53 ET | 2467 | 4.63 |
| 01:55 ET | 309 | 4.58 |
| 01:57 ET | 502 | 4.65 |
| 02:00 ET | 4399 | 4.6 |
| 02:02 ET | 3634 | 4.56 |
| 02:04 ET | 5698 | 4.39 |
| 02:20 ET | 245 | 4.51 |
| 02:24 ET | 8300 | 4.495 |
| 02:26 ET | 500 | 4.58 |
| 02:27 ET | 1501 | 4.61 |
| 02:31 ET | 100 | 4.67 |
| 02:40 ET | 105 | 4.63 |
| 02:45 ET | 100 | 4.67 |
| 02:51 ET | 2002 | 4.58 |
| 02:56 ET | 100 | 4.69 |
| 03:00 ET | 200 | 4.7 |
| 03:05 ET | 1200 | 4.67 |
| 03:07 ET | 100 | 4.65 |
| 03:09 ET | 100 | 4.65 |
| 03:12 ET | 407 | 4.65 |
| 03:20 ET | 200 | 4.75 |
| 03:23 ET | 100 | 4.82 |
| 03:25 ET | 320 | 4.83 |
| 03:32 ET | 2757 | 4.93 |
| 03:34 ET | 1200 | 4.9252 |
| 03:38 ET | 4794 | 4.8 |
| 03:45 ET | 5100 | 4.8301 |
| 03:50 ET | 200 | 4.89 |
| 03:54 ET | 500 | 4.93 |
| 03:56 ET | 300 | 4.93 |
| 03:57 ET | 200 | 4.85 |
| 03:59 ET | 2561 | 5.07 |
Apr 17, 2024
DJ AEON Biopharma Price Target Maintained With a $18.00/Share by HC Wainwright & Co., from 7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
Mar 30, 2024
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants, from 10:53PM ET on Saturday Mar 30, 2024 by Dow Jones
10:53PM ET on Saturday Mar 30, 2024 by Dow Jones
Mar 29, 2024
Press Release: AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results, from 3:45PM ET on Friday Mar 29, 2024 by Dow Jones
3:45PM ET on Friday Mar 29, 2024 by Dow JonesAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results, from 3:45PM ET on Friday Mar 29, 2024 by Dow Jones
3:45PM ET on Friday Mar 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aeon Biopharma Inc | 191.6M | -5.1x | --- |
Trevi Therapeutics Inc | 191.7M | -9.5x | --- |
Atossa Therapeutics Inc | 191.7M | -6.4x | --- |
Acumen Pharmaceuticals Inc | 190.5M | -2.9x | --- |
Outlook Therapeutics Inc | 188.0M | -2.1x | --- |
X4 Pharmaceuticals Inc | 195.6M | -1.9x | --- |
Company Information
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
Contact Information
- Headquarters
- 5 Park Plaza, Suite 1750IRVINE, CA, United States 92614
- Phone
- 949-354-6499
- Fax
- 302-655-5049
Executives
- Chairman Nominee of the Board
- Jost Fischer
- Chief Executive Officer, Director Nominee
- Marc Forth
- Chief Financial Officer
- Peter Reynolds
- Executive Vice President, Chief Legal Officer, Corporate Secretary
- Alex Wilson
- Chief Medical Officer
- Chad Oh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $191.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.99 |
Book Value | $-4.12 |
P/E Ratio | -5.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
